SOURCE: Wall Street News Alert

Wall Street News Alert

June 23, 2008 08:33 ET

Wall Street News Alert: OCOL Is Monday's Stock to Watch! June 23, 2008

WESTON, FL--(Marketwire - June 23, 2008) - Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), UnitedHealth Group Company (NYSE: UNH), Johnson & Johnson (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE).

There is more important news coming from Oncolin Therapeutics (OTCBB: OCOL), and the company should have investors monitoring the stock closely. Early this morning, the company issued a press release announcing that Dr. Daniel Von Hoff has joined the company's Scientific Advisory Board (SAB).

This new addition should be welcomed by the company as, according to the press release, Dr. Von Hoff is generally considered to be one of the world's leading experts in oncology drug development and is an advisor in some capacity to a large number of oncology companies. Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world's largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.

Daniel D. Von Hoff, M.D., is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and Chief Scientific Officer, Scottsdale Clinical Research Institute. He has done work on the development of many anticancer agents, including paclitaxel, docetaxel, gemcitabine, camptosar and hab-paclitaxel.

"Oncolin Therapeutics is very excited to have someone with Dr Von Hoff's stature and experience as a member of our SAB. His oncology development experience will be a major addition to our advisory board," said Dr. Donald Picker, COO of Oncolin

Investors are urged to continue to monitor the progress of the company! Last week the company reported that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) will be presenting its lead cancer technology at this prestigious symposium in Geneva Switzerland in October 2008.

The press release states that targeted initially for brain tumors, this technology is a major breakthrough in inhibiting glycolysis, a process many tumor cells, but not normal cells, require for growth and survival. This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson Cancer Center, the # 1 cancer treatment center in the United State according to U.S. News and World Report.

Prior to the latest press release, the stock closed Friday at Twenty cents a share.

For an in-depth profile of Oncolin Therapeutics, visit http://www.WallStreetNewsAlert.com/HotStocks/OCOL062208/default.aspx.

UnitedHealth Group Company (NYSE: UNH) down 2.7% on 17.6 million shares traded. UnitedHealthcare (www.unitedhealthcare.com) provides a full spectrum of consumer-oriented health benefit plans and services.

Johnson & Johnson (NYSE: JNJ) down 0.8% on 16.4 million shares traded. Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets.

Pfizer Inc. (NYSE: PFE) down 2.4% on 63.3 million shares traded. Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. The company discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.

Market Commentary:

"Americans are still feeling it at the pump, as of June 16, the average price of a gallon of gasoline was $4.13 a gallon. A year ago, it was $3.06 a gallon," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: http://www.WallStreetNewsAlert.com.

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at info@wallstreetnewsalert.com or see our services at http://www.wallstreetnewsalert.com/tPage.aspx?PAGE_TYPE=AU

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 100 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com and select the "join now" button.

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. For current services performed for Oncolin Therapeutics (OTCBB: OCOL), WSCF has been compensated Ninety Thousand shares of Oncolin Therapeutics, by a third party (Jonathan Camarillo Trust), who is non-affiliated and may hold a significant position in the stock. WSCF holds Fifty Two Thousand of those shares as of this release, and intends to immediately continue selling its shares as this release is being circulated. WSCF has also been previously compensated Twenty Seven Thousand Dollars for coverage of Oncolin Therapeutics (OTCBB: OCOL), previously known as Edgeline Holdings, Inc., by the company, for services provided including dissemination of company information in this release. Prior to the name and symbol change, WSCF was previously compensated for services rendered in 2008 and 2007; the previous compensation can be viewed by looking at a previous WSNA, ELHI press release. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information